AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it plans to release interim six-month data from the dose escalation groups, and an update of enrollment for its ongoing CNGB3 and CNGA3 Phase 1/2 clinical trials in patients with achromatopsia (ACHM) on January 23, 2020. AGTC management will host a conference call and webcast with accompanying slides to review the data beginning at 8:00 a.m. Eastern time on the same date.

The live webcast will be available in the Events and Presentations section of the Investor Relations page at . To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). The archived webcast and slide presentation will be available in the Events and Presentations section of the Company's website.

About AGTC

AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, in which it has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS) and other CNS, ophthalmology and indications. The optogenetics program is being developed in collaboration with Bionic Sight. The otology program is being developed in collaboration with Otonomy. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.

IR/PR CONTACTS: 

David Carey (IR) or Glenn Silver (PR)

Lazar FINN Partners

T: (212) 867-1768 or (646) 871-8485

or

Corporate Contacts:

Bill Sullivan

Chief Financial Officer

Applied Genetic Technologies Corporation

T: (617) 843-5728  

Stephen Potter

Chief Business Officer

Applied Genetic Technologies Corporation

T: (617) 413-2754